Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Khellin and visnagin differentially modulate AHR signaling and downstream CYP1A activity in human liver cells

R. Vrzal, K. Frauenstein, P. Proksch, J. Abel, Z. Dvorak, T. Haarmann-Stemmann,

. 2013 ; 8 (9) : e74917.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Khellin and visnagin are two furanochromones that can be frequently found in ethnomedical formulations in Asia and the Middle East. Both compounds possess anti-inflammatory and analgesic properties, therefore modern medicine uses these compounds or structurally related derivatives for treatment of vitiligo, bronchial asthma and renal colics. Despite their frequent usage, the potential toxic properties of visnagin and khellin are not well characterized up-to-now. Many natural compounds modulate the expression and activity of cytochrome P450 1A1 (CYP1A1), which is well-known to bioactivate pro-carcinogens. The expression of this enzyme is controlled by the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor and regulator of drug metabolism. Here, we investigated the influence of both furanochromones on AHR signaling in human HepG2 hepatocarcinoma cells and primary human hepatocytes. Both compounds transactivated xenobiotic response element (XRE)-driven reporter gene activity in a dose-dependent manner and induced CYP1A1 transcription in HepG2 cells and primary hepatocytes. The latter was abolished in presence of a specific AHR antagonist. CYP1A enzyme activity assays done in HepG2 cells and primary hepatocytes revealed an inhibition of enzyme activity by both furanochromones, which may become relevant regarding the metabolism of xenobiotics and co-administered therapeutic drugs. The observed induction of several other members of the AHR gene battery, whose gene products are involved in regulation of cell growth, differentiation and migration, indicates that a further toxicological characterization of visnagin and khelllin is urgently required in order to minimize potential drug-drug interactions and other toxic side-effects that may occur during therapeutic usage of these furanochromones.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14063937
003      
CZ-PrNML
005      
20140707113459.0
007      
ta
008      
140704s2013 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0074917 $2 doi
035    __
$a (PubMed)24069365
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vrzal, Radim $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Olomouc, Czech Republic.
245    10
$a Khellin and visnagin differentially modulate AHR signaling and downstream CYP1A activity in human liver cells / $c R. Vrzal, K. Frauenstein, P. Proksch, J. Abel, Z. Dvorak, T. Haarmann-Stemmann,
520    9_
$a Khellin and visnagin are two furanochromones that can be frequently found in ethnomedical formulations in Asia and the Middle East. Both compounds possess anti-inflammatory and analgesic properties, therefore modern medicine uses these compounds or structurally related derivatives for treatment of vitiligo, bronchial asthma and renal colics. Despite their frequent usage, the potential toxic properties of visnagin and khellin are not well characterized up-to-now. Many natural compounds modulate the expression and activity of cytochrome P450 1A1 (CYP1A1), which is well-known to bioactivate pro-carcinogens. The expression of this enzyme is controlled by the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor and regulator of drug metabolism. Here, we investigated the influence of both furanochromones on AHR signaling in human HepG2 hepatocarcinoma cells and primary human hepatocytes. Both compounds transactivated xenobiotic response element (XRE)-driven reporter gene activity in a dose-dependent manner and induced CYP1A1 transcription in HepG2 cells and primary hepatocytes. The latter was abolished in presence of a specific AHR antagonist. CYP1A enzyme activity assays done in HepG2 cells and primary hepatocytes revealed an inhibition of enzyme activity by both furanochromones, which may become relevant regarding the metabolism of xenobiotics and co-administered therapeutic drugs. The observed induction of several other members of the AHR gene battery, whose gene products are involved in regulation of cell growth, differentiation and migration, indicates that a further toxicological characterization of visnagin and khelllin is urgently required in order to minimize potential drug-drug interactions and other toxic side-effects that may occur during therapeutic usage of these furanochromones.
650    _2
$a aromatické hydroxylasy $x metabolismus $7 D001189
650    _2
$a buněčné linie $7 D002460
650    _2
$a cytochrom P-450 CYP1A1 $x genetika $x metabolismus $7 D019363
650    _2
$a aktivace enzymů $x účinky léků $7 D004789
650    _2
$a exprese genu $7 D015870
650    _2
$a regulace genové exprese $x účinky léků $7 D005786
650    _2
$a reportérové geny $7 D017930
650    _2
$a hepatocyty $x účinky léků $x metabolismus $7 D022781
650    _2
$a lidé $7 D006801
650    _2
$a khelin $x farmakologie $7 D007666
650    _2
$a receptory aromatických uhlovodíků $x metabolismus $7 D018336
650    _2
$a signální transdukce $x účinky léků $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Frauenstein, Katrin
700    1_
$a Proksch, Peter
700    1_
$a Abel, Josef $7 gn_A_00000524
700    1_
$a Dvorak, Zdenek
700    1_
$a Haarmann-Stemmann, Thomas
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 8, č. 9 (2013), s. e74917
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24069365 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140707113747 $b ABA008
999    __
$a ok $b bmc $g 1031421 $s 862669
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 8 $c 9 $d e74917 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20140704

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...